Therapy of classical Hodgkin's lymphoma and other CD30+ lymphomas has considerably improved during the last two decades [1]; the long-term toxicity of current regimens, however, is still strikingly high, providing a need for alternative strategies. Here, TNFRSF8 is linked to lymphoma.